After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …

Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Cancer cells evade T cell-mediated killing through tumour–immune interactions whose
mechanisms are not well understood,. Dendritic cells (DCs), especially type-1 conventional …

Mucosal vaccines offer the potential to trigger robust protective immune responses at the
predominant sites of pathogen infection. In principle, the induction of adaptive immunity at …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

The tumor microenvironment (TME) influences cancer progression and therapy response.
Therefore, understanding what regulates the TME immune compartment is vital. Here we …

Tumors are populated by antigen-presenting cells (APCs) including macrophage subsets
with distinct origins and functions. Here, we examined how cancer impacts mononuclear …

According to the widely accepted" three Es" model, the host immune system eliminates
malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium …